Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.